Proteomics-inspired precision medicine for treating and understanding multiple myeloma

Area of Science:

• Oncology
• Proteomics
• Precision Medicine

Background:

• Multiple myeloma (MM) management has advanced due to molecular characterization and novel therapies, significantly improving survival.
• Despite progress, MM remains incurable, and current risk-adaptive strategies do not fully integrate modern treatment outcomes.
• Existing treatment selection relies on outdated methods, necessitating updated risk stratification.

Purpose of the Study:

• To review current risk-adaptive strategies in multiple myeloma.
• To explore the clinical application of proteomics for monitoring treatment response, disease progression, and minimal residual disease (MRD).
• To discuss promising biomarkers and immunomics-based approaches for novel therapeutic development.

Main Methods:

• Review of current risk-adaptive strategies in multiple myeloma.
• Discussion of proteomics applications in MM monitoring.
• Exploration of biomarkers for disease progression, treatment response, and chemoresistance.
• Examination of immunomics-based approaches for therapeutic development.

Main Results:

• Proteomics shows potential in monitoring treatment response and disease progression in MM.
• Biomarkers are crucial for stratifying patients based on sensitivity to chemotherapy.
• Immunomics-based strategies are emerging for developing monoclonal antibodies, vaccines, and CAR-T cells.

Conclusions:

• The integration of proteomics in multiple myeloma research facilitates precision medicine.
• Identifying robust biomarkers is essential for tailoring treatments in the era of immunotherapy and targeted therapy.
• Multiple myeloma, with its dependence on protein homeostasis, is an ideal model for advancing proteomics in clinical applications.